Publication details

Praxe podávání systémových kortikosteroidů kriticky nemocným pacientům s covidem-19 v České republice – dotazníkový průzkum (studie ASAP-C)

Title in English Clinical practise of administration of systemic corticosteroids among critically ill patients with COVID-19 in the Czech Republic: survey (ASAP-C)
Authors

MALÁSKA Jan KELLER Filip CHEBEK D. STAŠEK Jan HUDEC Jan PROKOPOVÁ Tereza KRATOCHVÍL Milan DUŠKA František MÁCA J. BRAT Kristián ŠTĚPÁNOVÁ R. SVOBODNÍK Adam KLUČKA Jozef ŠTOURAČ Pavel

Year of publication 2022
Type Article in Periodical
Magazine / Source Anesteziologie a intenzivní medicína
MU Faculty or unit

Faculty of Medicine

Citation
Web Scopus
Doi http://dx.doi.org/10.36290/aim.2022.006
Keywords ARDS; corticosteroids; COVID-19; critical care; survey
Description Study objective: Administration of systemic corticosteroids in patients with severe COVID-19 (Coronavirus Disease 2019) has been recommended by World Health Organization (WHO) according to the RECOVERY trial results. However, there is still ongoing debate regarding the evidence supporting the dose, timing, route of administration and type of corticosteroid. This survey aimed to describe the current clinical practice of administration of systemic corticosteroids for patients with COVID-19 within Intensive Care Units (ICU) in Czech Republic. Study design: cross-sectional survey Material and methods: Electronic survey containing 15 questions was sent to the members of Czech Society of Anaesthesiol-ogy, Resuscitation and Intensive Care, Czech Society of Intensive care and Czech Pneumological and Phthisiological Society members. The results were analysed by descriptive statistic methods. Results: The survey fulfilled 233 respondents and 231 answers were eligible for analysis. The most prevalent group was attending physician with completed training in anaesthesiology and intensive care medicine (AIM) (32 %, n = 74). The most prevalent indication for initiation of corticosteroid treatment was oxygen therapy (face mask or nasal cannula) (59,3 %, n = 137) and high-flow nasal oxygen therapy (HFNC) (21,6 %, n = 50). The most preferred corticosteroid was dexamethasone (75,8 %, n = 175) at dose of 8 mg intravenously (i. v.) (48,6 %, n = 85), or dose of 6 mg i. v. (32,0 %, n = 56) followed by methylprednis-olone (25,5 %, n= 59) at dose of 80 mg i. v. (35,6 %, n = 21), and 40 mg i. v. (13,6 %, n = 8), respectively. The preferred duration of therapy was 10 days (dexamethasone 60,6 %, n = 106, methylprednisolone 20,3 %, n = 12). Conclusion: Administration of corticosteroid was dominantly initiated in patients with severe COVID-19 receiving supplemental oxygen. The corticosteroid of first choice was intravenous dexamethasone at dose of 8 mg and 6 mg for 10 days, respectively. © 2022, Czech Medical Association J.E. Purkyne. All rights reserved.

You are running an old browser version. We recommend updating your browser to its latest version.

More info